Zanoterone
Product Specifications
UNSPSC Description
Zanoterone is an orally active antagonist of the androgen receptor (AR) with a Ki of 2.2 μM. Zanoterone blocks the binding of androgens such as testosterone and dihydrotestosterone (DHT), inhibiting the androgen signaling pathway, thereby reducing androgen-dependent prostate hyperplasia and prostate cancer growth[1].
Target Antigen
Androgen Receptor
Type
Reference compound
Related Pathways
Vitamin D Related/Nuclear Receptor
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Cancer; Endocrinology
Assay Protocol
https://www.medchemexpress.com/zanoterone.html
Solubility
10 mM in DMSO
Smiles
C[C@@]12[C@]3([H])[C@](CC[C@@]1([H])CC4=NN(S(C)(=O)=O)C=C4C2)([H])[C@@]5([H])[C@](CC3)([C@@](O)(CC5)C#C)C
Molecular Weight
416.58
References & Citations
[1]Juniewicz PE, et al. Effect of combination treatment with zanoterone (WIN 49596), a steroidal androgen receptor antagonist, and finasteride (MK-906), a steroidal 5 alpha-reductase inhibitor, on the prostate and testes of beagle dogs. Endocrinology. 1993 Aug;133(2):904-13.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-105122/Zanoterone-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-105122/
Clinical Information
Phase 3
CAS Number
107000-34-0
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
